These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 16918926)

  • 21. [Integrating HPV testing for primary screening?].
    Riethmuller D; Ramanah R; Pretet JL; Mougin C
    J Gynecol Obstet Biol Reprod (Paris); 2008 Feb; 37 Suppl 1():S139-51. PubMed ID: 18191912
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Frequency and outcome of cervical cancer prevention failures in the United States.
    Raab SS; Grzybicki DM; Zarbo RJ; Jensen C; Geyer SJ; Janosky JE; Meier FA; Vrbin CM; Carter G; Geisinger KR
    Am J Clin Pathol; 2007 Nov; 128(5):817-24. PubMed ID: 17951205
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost-effectiveness of adding human papilloma virus testing to a managed care cervical cancer screening program.
    Lonky NM; Hunter MI; Sadeghi M; Edwards G; Bajamundi K; Monk BJ
    J Low Genit Tract Dis; 2007 Oct; 11(4):258-64. PubMed ID: 17917570
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of cervical cancer screening program at a rural community of South Africa.
    Hoque M; Hoque E; Kader SB
    East Afr J Public Health; 2008 Aug; 5(2):111-6. PubMed ID: 19024420
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Organisation of cervical cytology screening in Croatia: past, present and future.
    Pajtler M; Audy-Jurković S; Kardum-Skelin I; Mahovlić V; Mozetic-Vrdoljak D; Ovanin-Rakić A
    Coll Antropol; 2007 Apr; 31 Suppl 2():47-54. PubMed ID: 17598505
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Assessing new technologies for cervical cancer screening: beyond sensitivity.
    Massad LS
    J Low Genit Tract Dis; 2008 Oct; 12(4):311-5. PubMed ID: 18820547
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Integrating human papillomavirus vaccination in cervical cancer control programmes.
    Franco EL; Coutlée F; Ferenczy A
    Public Health Genomics; 2009; 12(5-6):352-61. PubMed ID: 19684447
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Cervical cancer screening and associated treatment costs in France].
    Bergeron C; Breugelmans JG; Bouée S; Lorans C; Bénard S; Rémy V
    Gynecol Obstet Fertil; 2006 Nov; 34(11):1036-42. PubMed ID: 17070085
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Decisions about Pap tests: what influences women and providers?
    Fiebig DG; Haas M; Hossain I; Street DJ; Viney R
    Soc Sci Med; 2009 May; 68(10):1766-74. PubMed ID: 19339094
    [TBL] [Abstract][Full Text] [Related]  

  • 30. On sample size for sensitivity and specificity in prospective diagnostic accuracy studies.
    Li J; Fine J
    Stat Med; 2004 Aug; 23(16):2537-50. PubMed ID: 15287083
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cervical cancer screening in the 21st century: is it time to retire the PAP smear?
    Wright TC
    Clin Obstet Gynecol; 2007 Jun; 50(2):313-23. PubMed ID: 17513921
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative study of four candidate strategies to detect cervical cancer in different health care settings.
    Kamal MM; Sapkal RU; Sarodey CS; Munshi MM; Alsi YD; Chande MA; Hingway SR; Dandige S; Kane US; Kshirsagar R; Tangsale M; Zodpey S; Patel AB; Mamtani M; Kulkarni H
    J Obstet Gynaecol Res; 2007 Aug; 33(4):480-9. PubMed ID: 17688615
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Invasive cervical cancer: a failure of screening.
    Spayne J; Ackerman I; Milosevic M; Seidenfeld A; Covens A; Paszat L
    Eur J Public Health; 2008 Apr; 18(2):162-5. PubMed ID: 17483491
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bayesian sample size determination for prevalence and diagnostic test studies in the absence of a gold standard test.
    Dendukuri N; Rahme E; Bélisle P; Joseph L
    Biometrics; 2004 Jun; 60(2):388-97. PubMed ID: 15180664
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A likelihood ratio test for cancer screening trials.
    Self SG; Etzioni R
    Biometrics; 1995 Mar; 51(1):44-50. PubMed ID: 7766795
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cervical cancer screening in Thailand: an overview.
    Sriamporn S; Khuhaprema T; Parkin M
    J Med Screen; 2006; 13 Suppl 1():S39-43. PubMed ID: 17227641
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Is there a language divide in pap test use?
    Ponce NA; Chawla N; Babey SH; Gatchell MS; Etzioni DA; Spencer BA; Brown ER; Breen N
    Med Care; 2006 Nov; 44(11):998-1004. PubMed ID: 17063131
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of an antepartum Pap smear on the coverage of a cervical cancer screening programme: a population-based prospective study.
    Nygård M; Daltveit AK; Thoresen SO; Nygård JF
    BMC Health Serv Res; 2007 Jan; 7():10. PubMed ID: 17244348
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Human papillomavirus testing for primary cervical cancer screening.
    Grce M; Davies P
    Expert Rev Mol Diagn; 2008 Sep; 8(5):599-605. PubMed ID: 18785808
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cervical cancer screening and management practices among providers in the National Breast and Cervical Cancer Early Detection Program (NBCCEDP).
    Saraiya M; Irwin KL; Carlin L; Chen X; Jain N; Benard V; Montano DE
    Cancer; 2007 Sep; 110(5):1024-32. PubMed ID: 17628488
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.